1	Una	Una		C0205447_1	calificador_1	0-3	474_QUEST_clinical_caseMIR	SENT1	-	-
2	mujer	mujer	NCFS000	C0043210#C0015780#C0086418	persona#hallazgo#estructura_corporal#organismo_vivo	4-9	474_QUEST_clinical_caseMIR	SENT1	-	-
3	de	de	SPS00	C0332285	atributo	10-12	474_QUEST_clinical_caseMIR	SENT1	-	-
4	27	27		-	-	13-15	474_QUEST_clinical_caseMIR	SENT1	-	-
5	años	año	NCMP000	C0439234	calificador	16-20	474_QUEST_clinical_caseMIR	SENT1	-	-
6	de	de	SPS00	C0001779_1	entidad_observable_1	21-23	474_QUEST_clinical_caseMIR	SENT1	-	-
7	edad	edad	NCFS000	C0001779_2	entidad_observable_2	24-28	474_QUEST_clinical_caseMIR	SENT1	-	-
8	consulta	consultar	VMM02S0	C1704447_1	calificador_1	29-37	474_QUEST_clinical_caseMIR	SENT1	-	-
9	por	por	SPS00	C1704447_2	calificador_2	38-41	474_QUEST_clinical_caseMIR	SENT1	-	-
10	presentar	presentar	VMN0000	-	-	42-51	474_QUEST_clinical_caseMIR	SENT1	-	-
11	amenorrea	amenorrea	NCFS000	C0232940_1	hallazgo_1	52-61	474_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
12	secundaria	secundario	AQ0FS0	C0232940_2	hallazgo_2	62-72	474_QUEST_clinical_caseMIR	SENT1	-	-
13	de	de	SPS00	C0332285	atributo	73-75	474_QUEST_clinical_caseMIR	SENT1	-	-
14	un	un		C0205447_1	calificador_1	76-78	474_QUEST_clinical_caseMIR	SENT1	-	-
15	año	año	NCMS000	C0439234	calificador	79-82	474_QUEST_clinical_caseMIR	SENT1	-	-
16	de	de	SPS00	C0332285	atributo	83-85	474_QUEST_clinical_caseMIR	SENT1	-	-
17	evolución	evolución	NCFS000	-	-	86-95	474_QUEST_clinical_caseMIR	SENT1	-	-
18	.	.	Fp	-	-	95-96	474_QUEST_clinical_caseMIR	SENT1	-	-

1	No	no	RN	C1298908	calificador	97-99	474_QUEST_clinical_caseMIR	SENT2	-	-
2	refiere	referir	VMIP3S0	-	-	100-107	474_QUEST_clinical_caseMIR	SENT2	-	-
3	antecedentes	antecedente	NCMP000	-	-	108-120	474_QUEST_clinical_caseMIR	SENT2	-	-
4	yatrogénicos	yatrogénico	AQ0MP0	-	-	121-133	474_QUEST_clinical_caseMIR	SENT2	-	-
5	.	.	Fp	-	-	133-134	474_QUEST_clinical_caseMIR	SENT2	-	-

1	Analíticamente	analíticamente	RG	-	-	135-149	474_QUEST_clinical_caseMIR	SENT3	-	-
2	,	,	Fc	-	-	149-150	474_QUEST_clinical_caseMIR	SENT3	-	-
3	la	el	DA0FS0	-	-	151-153	474_QUEST_clinical_caseMIR	SENT3	-	-
4	concentración	concentración	NCFS000	C0086045	entidad_observable	154-167	474_QUEST_clinical_caseMIR	SENT3	-	-
5	de	de	SPS00	C0332285	atributo	168-170	474_QUEST_clinical_caseMIR	SENT3	-	-
6	estradiol	estradiol	NCMS000	C0014912	sustancia	171-180	474_QUEST_clinical_caseMIR	SENT3	-	-
7	es	ser	VSIP3S0	-	-	181-183	474_QUEST_clinical_caseMIR	SENT3	-	-
8	inferior	inferior	AQ0CS0	C0542339#C0205104	calificador	184-192	474_QUEST_clinical_caseMIR	SENT3	-	-
9	a	a	SPS00	-	-	193-194	474_QUEST_clinical_caseMIR	SENT3	-	-
10	la	el	DA0FS0	-	-	195-197	474_QUEST_clinical_caseMIR	SENT3	-	-
11	normalidad	normalidad	NCFS000	-	-	198-208	474_QUEST_clinical_caseMIR	SENT3	-	-
12	y	y	CC	C1706368	calificador	209-210	474_QUEST_clinical_caseMIR	SENT3	-	-
13	el	el	DA0MS0	-	-	211-213	474_QUEST_clinical_caseMIR	SENT3	-	-
14	valor	valor	NCMS000	C0475208	calificador	214-219	474_QUEST_clinical_caseMIR	SENT3	-	-
15	de	de	SPS00	C0332285	atributo	220-222	474_QUEST_clinical_caseMIR	SENT3	-	-
16	prolactina	prolactina	NCFS000	C0033371	sustancia#producto	223-233	474_QUEST_clinical_caseMIR	SENT3	-	-
17	es	ser	VSIP3S0	-	-	234-236	474_QUEST_clinical_caseMIR	SENT3	-	-
18	de	de	SPS00	C0332285	atributo	237-239	474_QUEST_clinical_caseMIR	SENT3	-	-
19	12	12		-	-	240-242	474_QUEST_clinical_caseMIR	SENT3	-	-
20	ng	nasogástrico	NC00YL0	-	-	243-245	474_QUEST_clinical_caseMIR	SENT3	-	-
21	/	/	Fh	-	-	245-246	474_QUEST_clinical_caseMIR	SENT3	-	-
22	mL	mililitro	NCMN000	C0439242	calificador	246-248	474_QUEST_clinical_caseMIR	SENT3	-	-
23	.	.	Fp	-	-	248-249	474_QUEST_clinical_caseMIR	SENT3	-	-

1	Indique	indicar	VMM03S0	-	-	250-257	474_QUEST_clinical_caseMIR	SENT4	-	-
2	cuál	cuál	PT0CS000	-	-	258-262	474_QUEST_clinical_caseMIR	SENT4	-	-
3	de	de	SPS00	C0332285	atributo	263-265	474_QUEST_clinical_caseMIR	SENT4	-	-
4	las	el	DA0FP0	-	-	266-269	474_QUEST_clinical_caseMIR	SENT4	-	-
5	exploracio_x0002_nes	exploracio_x0002_nes		-	-	270-290	474_QUEST_clinical_caseMIR	SENT4	-	-
6	que	que	PR0CN000	-	-	291-294	474_QUEST_clinical_caseMIR	SENT4	-	-
7	se	se	P00CN000	-	-	295-297	474_QUEST_clinical_caseMIR	SENT4	-	-
8	citan	citar	VMIP3P0	-	-	298-303	474_QUEST_clinical_caseMIR	SENT4	-	-
9	a	a	SPS00	-	-	304-305	474_QUEST_clinical_caseMIR	SENT4	-	-
10	continuación	continuación	NCFS000	-	-	306-318	474_QUEST_clinical_caseMIR	SENT4	-	-
11	solicitaría	solicitar	VMIC3S0	-	-	319-330	474_QUEST_clinical_caseMIR	SENT4	-	-
12	como	como	CS	C0332257	calificador	331-335	474_QUEST_clinical_caseMIR	SENT4	-	-
13	primera	1	AO0FS0	-	-	336-343	474_QUEST_clinical_caseMIR	SENT4	-	-
14	medida	medida	NCFS000	C0079809	atributo	344-350	474_QUEST_clinical_caseMIR	SENT4	-	-
15	para	para	SPS00	C0521125	calificador	351-355	474_QUEST_clinical_caseMIR	SENT4	-	-
16	tratar	tratar	VMN0000	-	-	356-362	474_QUEST_clinical_caseMIR	SENT4	-	-
17	de	de	SPS00	C0332285	atributo	363-365	474_QUEST_clinical_caseMIR	SENT4	-	-
18	filiar	filiar	VMN0000	-	-	366-372	474_QUEST_clinical_caseMIR	SENT4	-	-
19	el	el	DA0MS0	-	-	373-375	474_QUEST_clinical_caseMIR	SENT4	-	-
20	origen	origen	NCMS000	C0439659	atributo	376-382	474_QUEST_clinical_caseMIR	SENT4	-	-
21	del	del	SP+DA	-	-	383-386	474_QUEST_clinical_caseMIR	SENT4	-	-
22	trastorno	trastorno	NCMS000	C0012634#C0039082	trastorno	387-396	474_QUEST_clinical_caseMIR	SENT4	-	-
23	:	:	Fd	-	-	396-397	474_QUEST_clinical_caseMIR	SENT4	-	-
24	.	.	Fp	-	-	397-398	474_QUEST_clinical_caseMIR	SENT4	-	-

